Captopril-associated 'pseudocholangitis': A case report and review of the literature

Aviram Nissan*, Ram M. Spira, Dan Seror, Zvi Ackerman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Captopril, a competitive inhibitor of angiotensin-converting enzyme, is widely used in the treatment of hypertension and heart failure. Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects. However, hepatotoxicity is extremely rare. A patient with severe cholestatic jaundice induced by captopril is presented. On admission to the hospital, the patient was diagnosed and treated as having cholangitis. Review of the literature showed similar occurrences in other patients. Patients treated with captopril who develop 'atypical cholangitis' should be suspected of having captopril-associated liver damage.

Original languageEnglish
Pages (from-to)670-671
Number of pages2
JournalArchives of Surgery
Volume131
Issue number6
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Dive into the research topics of 'Captopril-associated 'pseudocholangitis': A case report and review of the literature'. Together they form a unique fingerprint.

Cite this